164 related articles for article (PubMed ID: 31938346)
21. Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.
Sapio L; Sorvillo L; Illiano M; Chiosi E; Spina A; Naviglio S
Molecules; 2015 Sep; 20(9):15910-28. PubMed ID: 26340617
[TBL] [Abstract][Full Text] [Related]
22. KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib.
Fleisher B; Werkman C; Jacobs B; Varkey J; Taha K; Ait-Oudhia S
Cancer Diagn Progn; 2022; 2(5):525-532. PubMed ID: 36060015
[TBL] [Abstract][Full Text] [Related]
23. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
[TBL] [Abstract][Full Text] [Related]
24. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
Yousefi H; Khosla M; Lauterboeck L; Okpechi SC; Worthylake D; Garai J; Zabaleta J; Guidry J; Zarandi MA; Wyczechowska D; Jayawickramarajah J; Yang Q; Kissil J; Alahari SK
Oncogene; 2022 Nov; 41(47):5076-5091. PubMed ID: 36243802
[TBL] [Abstract][Full Text] [Related]
25. Diallyl trisulfide suppresses doxorubicin-induced cardiomyocyte apoptosis by inhibiting MAPK/NF-κB signaling through attenuation of ROS generation.
Wen SY; Tsai CY; Pai PY; Chen YW; Yang YC; Aneja R; Huang CY; Kuo WW
Environ Toxicol; 2018 Jan; 33(1):93-103. PubMed ID: 29087013
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells.
Labbozzetta M; Poma P; Vivona N; Gulino A; D'Alessandro N; Notarbartolo M
Oncol Lett; 2015 Dec; 10(6):3807-3815. PubMed ID: 26788213
[TBL] [Abstract][Full Text] [Related]
27. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
28. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
30. Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts.
Xu S; Zheng S; Ma N; Zhang H; Shi J; Huang J; Luo N; Wang M; Xiong Y
Biochem Pharmacol; 2024 May; 223():116139. PubMed ID: 38499109
[TBL] [Abstract][Full Text] [Related]
31. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
32. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
33. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.
Elbaz M; Ahirwar D; Xiaoli Z; Zhou X; Lustberg M; Nasser MW; Shilo K; Ganju RK
Oncotarget; 2018 Sep; 9(71):33459-33470. PubMed ID: 30323891
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
[TBL] [Abstract][Full Text] [Related]
35. KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.
Wen T; Geng M; Bai E; Wang X; Miao H; Chen Z; Zhou H; Wang J; Shi J; Zhang Y; Lei M; Zhu Y
FEBS Open Bio; 2023 Apr; 13(4):751-762. PubMed ID: 36847599
[TBL] [Abstract][Full Text] [Related]
36. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
37. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
[TBL] [Abstract][Full Text] [Related]
38. Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer.
Larsson P; Pettersson D; Olsson M; Sarathchandra S; Abramsson A; Zetterberg H; Ittner E; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ
Cell Death Discov; 2024 Jan; 10(1):57. PubMed ID: 38286854
[TBL] [Abstract][Full Text] [Related]
39. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.
Pang Y; Shi R; Chan L; Lu Y; Zhu D; Liu T; Yan M; Wang Y; Wang W
Pharmacol Res; 2023 Oct; 196():106926. PubMed ID: 37716547
[TBL] [Abstract][Full Text] [Related]
40. Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Guo KY; Han L; Li X; Yang AV; Lu J; Guan S; Li H; Yu Y; Zhao Y; Yang J; Zhang H
Oncotarget; 2017 Dec; 8(69):114123-114135. PubMed ID: 29371974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
